ALLURION TECHNOLOGIES, INC.

ALUR
About the company

Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program. The company is headquartered in Natick, Massachusetts.

Country: United StatesPrice: $0.00Market Cap: $1,215

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

2 / 14

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 16 investors flag at least one profitability criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Annual history · FY 2025

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-03-31 · TTM ended 2026-03-31 vs 2025-03-31 · TTM ended 2026-03-31

Latest source filing: 2026-05-15

Score computed: 2026-11-14

TTM ended 2026-03-31

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Market data at 2026-11-01

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-03-31 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-03-31

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Market data at 2026-11-01

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2026-06-30–2026-11-01 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-30

Score computed: 2026-11-14

TTM ended 2026-03-31 · Balance sheet at 2026-03-31 · Price history 2026-06-30–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-30

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-03-31

Latest source filing: 2026-05-15

Score computed: 2026-11-14

TTM ended 2026-03-31 · Annual history · FY 2025 · Price history 2026-06-30–2026-11-01

Latest source filing: 2026-05-15

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Profitability0% pass✓ 1✗ 34▾

      No clean pass — all 16 investors flag at least one profitability criterion

      Positive EPS (10 years)0/5 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)0/5 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-198.0% (latest)
      ✗BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-6.8M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROEN/A (negative equity)
      ✗Lynch> 15%
      EBIT / Enterprise Value-113.2%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-113.2%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-182.32%
      ✗PiotroskiROA > 0
      ROA Change YoY-21.94% -> -182.32% (delta: -160.38%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=-183.53%, ROA=-182.32%
      ✗PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY67.0% -> 62.8%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue-264.7%
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity
      ✗Dreman> 12%
      Margin of Safety
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency0/4 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-211.2%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-147.9% (2023) -> -198.0% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 77.6% -> 62.8%, operating margin -147.9% -> -198.0%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-2744773.66%; #6331/6340 (top 99.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+47.43%; #726/3702 (top 19.6%)
      ✓AsnessTop 30% of eligible cross-section
      Net income / positive book equity
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.5874; #5037/5884 (top 85.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-113.2%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-113.2%, ROC=N/A (invested capital <= 0)
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      Price / Book Value per ShareN/A (negative BVPS)
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-113085.7%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical Average
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share
      ✗Ackman<= 25
      Price vs. Trailing Low
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-2744773.66%; #6331/6340 (top 99.9%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization-64123.4568; #6443/6449 (top 99.9%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+10367.9012; #24/5247 (top 0.5%)
      ✓OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date
      ✗OshaughnessyTop 10% of eligible cross-section
    • Cash Flow0% pass✗ 12▾

      All 10 investors flag ALUR's cash flow

      Free Cash Flow Proxy$-6.8M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-42.9M
      ✗LynchPositive and growing
      Operating Cash Flow$-28.9M
      ✗PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=-183.53%, ROA=-182.32%
      ✗PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)N/A (negative CFPS)
      ✗Dreman< 8x
      P/E or FCF Yield
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive0/3 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap
      ✗Ackman>= 4%
      Price / FCF per Share
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency0/4 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✗ 13▾

      All 8 investors flag ALUR's growth

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -38.5% vs Rev: -55.5%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$-1.51 (2022) -> $-3.81 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency0/4 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth-39.9%
      ✗Ackman>= 5%
      Positive EPS Growth Frequency1/3 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 77.6% -> 62.8%, operating margin -147.9% -> -198.0%
      ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag ALUR's efficiency

      Current Ratio0.30
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-153.6%
      ✗Buffett> 10%
      ROIC - WACC-163.6%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.44 -> 0.33
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.98x -> 0.97x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.30
      ✗Dreman> 1.5
      Return on Invested CapitalN/A (non-positive invested capital)
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/1 years above 12% (latest -104.7%)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 14▾

      Split decision: 14 FAIL · 2 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 1)✗DremanFAIL (0/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (0/9)✗TempletonFAIL (1/8)✗SleepFAIL (1/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 2✗ 13▾

      11 of 12 flag ALUR's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current AssetsLT Debt $0.0M vs NCA $-26.0M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: N/A (negative equity), IC: N/A
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / EquityN/A (negative equity)
      ✗Lynch< 0.33
      Cash - Long-term Debt$5.1M
      ✓LynchPositive preferred
      LT Debt / Total Assets Change108.83% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.30
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt LevelsN/A (non-positive equity)
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Medical Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($1,215)
    Revenue: $15.2M-52.6% YoY
    Net Income: $28.8M-299.5% YoY

    Financial Snapshot

    Operating Margin-198.0%
    Return on Equity37.3%
    Debt / Equity-0.36
    Current Ratio0.33
    EPS (Diluted)$-3.81

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-03-31

    2025-04-01 – 2026-03-31

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, depreciation amortization.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-30
    FY 2024
    Sources
    • 10-K/A · 2025-08-19
    FY 2023
    Sources
    • 10-K · 2024-03-26
    FY 2022
    Sources
    • 10-K · 2024-03-26
    FY 2021
    Sources
    • 10-K · 2024-03-26
    Market Cap$1.2Kcurrent--$49.1Mest.--------
    Revenue$12.6M↓55%$2.9M↓47%$15.2M↓53%$32.1M↓40%$53.5M↓17%$64.2M--
    Operating Income-$26.6M↑42%-$3.7M↑49%-$30.2M↑40%-$50.2M↑37%-$79.1M↓147%-$32.0M--
    Net Income-$33.3M↓37%-$6.1M↓183%-$28.8M↓299%-$7.2M↑91%-$82.8M↓119%-$37.7M--
    EPS (Diluted)--$-0.46↓330%$-3.81↑67%$-11.64↓404%$-2.31↓53%$-1.51--
    Gross Margin52.7%↓21%41.7%↓44%62.8%↓6%67.0%↓14%77.6%↓2%79.0%—
    Operating Margin-211.2%↓30%-126.6%↑3%-198.0%↓27%-156.3%↓6%-147.9%↓197%-49.9%—
    ROE42.8%↑23%—37.3%↑304%9.2%↓92%116.2%↓1%116.8%—
    Total Debt$28.6M↓8%$28.6M↓8%$28.1M↓21%$35.7M↓8%$38.6M↓32%$56.5M--
    Shareholders' Equity-$77.9M↓12%-$77.9M↓12%-$77.2M↑1%-$78.0M↓9%-$71.3M↓121%-$32.3M↓768%$4.8M
    Current Ratio0.30↓85%0.30↓85%0.33↓77%1.44↑45%0.99↑73%0.57—
    Debt / Equity-0.37↑17%-0.37↑17%-0.36↑21%-0.46↑16%-0.54↑69%-1.75—
    Operating Cash Flow-$22.7M↑47%-$3.2M↑66%-$28.9M↑32%-$42.3M↑34%-$64.0M↓36%-$47.0M--
    Free Cash Flow-------$42.9M↑35%-$65.6M↓35%-$48.5M--

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Medical Equipment

    ALUR vs Peers — Financial Grading

    Revenue$15.2MBottom 25%
    Net Income$28.8MBottom 25%
    ROE37.3%Top 25%
    D/E-0.36Top 25%
    Op. Margin-198.0%Bottom 25%
    Curr. Ratio0.33Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    ALCON INCALC$35.6B$74.12$10.4B$980.0M4.4%0.2113.1%2.122/91/93/70/3F-Score 64/11
    KONINKLIJKE PHILIPS NVPHG$29.7B$30.34$21.0B$1.1B8.2%0.648.0%1.321/91/91/70/3F-Score 53/11
    WEST PHARMACEUTICAL SERVICES INCWST$29.0B$416.42$3.1B$493.7M15.5%0.0619.0%3.024/96/96/71/3F-Score 75/11
    SMITH & NEPHEW PLCSNN$13.1B$31.28$6.2B$625.0M11.8%0.5912.9%2.572/90/91/70/3F-Score 64/11
    MSA Safety IncMSA$6.7B$174.17$1.9B$278.9M20.4%0.4219.8%3.015/95/94/71/3F-Score 57/11
    STAAR SURGICAL COSTAA$1.3B$26.39$239.4M$80.4M-23.4%—-38.3%4.552/92/92/70/3F-Score 33/11
    ARTIVION, INC.AORT$931.9M$19.10$441.3M$9.8M2.2%0.487.6%3.532/90/90/70/3F-Score 71/11
    InMode Ltd.INMD$763.6M$13.27$370.5M$93.8M13.7%—23.0%9.885/93/90/73/3F-Score 44/11